IO Biotech announced that Faical Miyara, Ph.D., has been appointed as the company’s chief business officer. Dr. Miyara will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech’s CEO, Mai-Britt Zocca, Ph.D., and be a member of the company’s executive team, effective immediately. Most recently, he served as Vice President, Head of Business Development Oncology, then Head of External Innovation Oncology, Lead on Venture Capital Activities at Ipsen Biosciences.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOBT:
- IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
- IO Biotech reports Q4 EPS (40c), consensus (39c)
- IO Biotech to Present at 44th Annual Cowen Health Care Conference
